10x Genomics, Inc. reaffirmed revenue guidance for the year 2024. The company maintaining its previously announced full year 2024 revenue guidance of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.01 USD | -2.51% |
|
-1.37% | -65.15% |
12:05pm | Wolfe Research Downgrades 10x Genomics to Peer Perform From Outperform | MT |
25/06 | Guggenheim Downgrades 10x Genomics to Neutral From Buy | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.15% | 233.43Cr | |
-10.39% | 1.16TCr | |
-12.79% | 737.49Cr | |
+26.65% | 544.24Cr | |
-0.32% | 530.74Cr | |
-17.87% | 374.07Cr | |
+7.41% | 257.81Cr | |
+28.63% | 222.83Cr | |
-11.56% | 220.67Cr | |
-14.32% | 166.58Cr |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- 10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024